Recent Updates — VRTX
On October 20, 2026, Vertex Pharmaceuticals appointed Daniel Brennan as a new member of the Board of Directors. In connection with this appointment, the size of the Board was increased from ten to eleven members, and Mr. Brennan joined the Audit and Finance Committee. Mr. Brennan previously served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation until his retirement in June 2025. He also holds board seats at Waters Corporation and Madrigal Pharmaceuticals. Upon joining the Board, he received a $400,000 restricted stock unit award vesting in October 2027. Vertex Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cystic fibrosis and other serious diseases.
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027. Charles F. Wagner, Jr., will cease serving as CFO but remain Executive Vice President and Chief Operating Officer. Mr. Poole’s employment agreement includes a $750,000 base salary and a target annual bonus of 90% of base salary. The company operates in the biotechnology industry, focusing on developing therapies for cystic fibrosis and other serious diseases.
Vertex Pharmaceuticals reported second quarter 2026 total revenue of $3.33 billion, a 12% increase from the prior year period, driven by strong performance in cystic fibrosis therapies and growth in sickle cell disease and acute pain treatments. The company raised its full-year 2026 revenue guidance to $13.1 billion–$13.2 billion from $12.95 billion–$13.1 billion, while maintaining expense guidance for combined R&D, acquired IPR&D, and SG&A at $6.3 billion–$6.45 billion (GAAP). Vertex also announced it entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, with closing anticipated in the third quarter of 2026. Additionally, the U.S. FDA assigned a PDUFA target action date of November 30, 2026, for povetacicept in IgA nephropathy. Vertex Pharmaceuticals is a global biotechnology company that develops and commercializes transformative medicines for serious diseases including cystic fibrosis, sickle cell disease, and acute pain.
Vertex Pharmaceuticals Incorporated entered into a definitive merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. through a wholly owned subsidiary, Clark Merger Sub, Inc. Under the terms of the agreement, Crinetics shareholders will receive $85.00 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to stockholder approval and regulatory clearances. Vertex intends to finance the acquisition using cash on hand and new debt, supported by a $4.5 billion unsecured 364-day bridge loan facility provided by Bank of America, BofA Securities, and Morgan Stanley. Vertex Pharmaceuticals is a biotechnology company focused on developing medicines for serious diseases.